{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"69"}],"units":"Participants"}],"groups":[{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 70 mg/m\\^2 for initial tolerability study (closed) Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles 6 participants to bendamustine 70 mg/m\\^2/day, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"BG000","title":"Non-Randomized to 70 mg/m2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 for initial tolerability study (closed) Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine: 6 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated","id":"BG001","title":"Non-randomized to 90 mg/m^2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 Rituximab: 28 participants Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine:28 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"BG002","title":"Randomized to 90 mg/m^2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 2 (TAC 2) Rituximab + Pentostatin\n\nPentostatin: 28 participants to pentostatin 4 mg/m\\^2 days 1 and 15 of each cycle.\n\nRituximab: Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles\n\nAcetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated.\n\nIntravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"BG003","title":"Randomized to Pentostatin-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 or Rituxan + Pentostatin After initial tolerability studies are completed. Non-randomize up to 4 total participants to Bendamustine and/or Pentostatin with Rituximab Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine: 1-4 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle Pentostatin 1-4 participants to pentostatin 4 mg/m\\^2 days 1 and 15 of each cycle.\n\nAcetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"BG004","title":"Non-randomized to Bendamustine 90mg/m^2 or Pentostatin 4mg/m^2 With Rituximab"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"39"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"30"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.03","value":"66.65"},{"groupId":"BG001","spread":"3.14","value":"58.67"},{"groupId":"BG002","spread":"9.75","value":"61.87"},{"groupId":"BG003","spread":"12.23","value":"61.55"},{"groupId":"BG004","spread":"0","value":"71.2"},{"groupId":"BG005","spread":"10.14","value":"62.01"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"12"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"57"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"67"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"65"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"69"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}